https://www.selleckchem.com/products/azd3965.html The study showed that the administration of a food supplement and a topical solution, both containing nanosilicon, improves hydration, elasticity, and skin barrier function. The study showed that the administration of a food supplement and a topical solution, both containing nanosilicon, improves hydration, elasticity, and skin barrier function. Topical azelaic acid (AzA) is a common treatment for mild/moderate inflammatory rosacea. To assess the efficacy and tolerability of a novel formulation cream containing 15% AzA (anti-inflammatory/anti-oxidant/anti-microbial agent) combined with 1% dihydroavenanthramide D (anti-inflammatory/anti-itch) in inflammatory rosacea using clinical/instrumental evaluation. In this multicentre, prospective, open-label trial, 45 patients with mild/moderate inflammatory rosacea enrolled at the Dermatology Clinic of the University of Catania, Naples, and Rome (Italy) were instructed to apply the cream twice daily for 8weeks. Clinical evaluation was performed at baseline (T0) and at 8weeks (T1) by (1) Investigator Global Assessment (IGA) score based on a 5-point scale (from 0=clear/no erythema/papules/pustules to 4=severe erythema/several papules/pustules) and (2) inflammatory lesions count. Instrumental evaluation of erythema degree was performed by erythema-directed digital photography (EDDP) by a 5-point scale (from 0=no redness to 4=severe redness) at all time points. Tolerability was assessed by a self-administered questionnaire at 8weeks. Statistical analysis was performed using SAS version 9. Forty-four patients completed the study. At week 8, a significant decrease in baseline of IGA scores [median from 3 (T0) to 1 (T1)] and inflammatory lesions count [median from 8 (T0) to 1 (T1)] was recorded along with a significant reduction of erythema scores [median from 2 (T0) to 1 (T1)]. No relevant side effects were recorded. Our results suggest that this new non-irritating product represen